Take off with VistaGen Therapeutics Inc. (VTGN): Get ready for trading

VistaGen Therapeutics Inc. (NASDAQ: VTGN) stock jumped 4.56% on Monday to $0.18 against a previous-day closing price of $0.17. With 3.06 million shares changed hands, the volume of the stock remained lighter than its average volume of 6.01 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.1800 whereas the lowest price it dropped to was $0.1652. The 52-week range on VTGN shows that it touched its highest point at $1.79 and its lowest point at $0.08 during that stretch. Beta for the stock currently stands at 0.62.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VTGN was up-trending over the past week, with a rise of 11.88%, but this was up by 69.99% over a month. Three-month performance surged to 60.83% while six-month performance rose 19.41%. The stock lost -88.38% in the past year, while it has gained 73.79% so far this year. A look at the trailing 12-month EPS for VTGN yields -0.31 with Next year EPS estimates of -0.18. For the next quarter, that number is -0.05. This implies an EPS growth rate of 49.90% for this year and 33.30% for next year.

Float and Shares Shorts:

At present, 206.81 million VTGN shares are outstanding with a float of 205.00 million shares on hand for trading. On Oct 13, 2022, short shares totaled 6.39 million, which was 3.09% higher than short shares on Sep 14, 2022. In addition to Mr. Shawn K. Singh J.D. as the firm’s CEO & Director, Mr. Jerrold D. Dotson CPA, CPA serves as its CFO, VP & Sec.

Institutional Ownership:

Through their ownership of 67.97% of VTGN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 9.66% of VTGN, in contrast to 17.98% held by mutual funds. Shares owned by individuals account for 0.87%. As the largest shareholder in VTGN with 5.20% of the stake, BlackRock Fund Advisors holds 10,764,499 shares worth 10,764,499. A second-largest stockholder of VTGN, Franklin Advisers, Inc., holds 9,096,538 shares, controlling over 4.40% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in VTGN, holding 5,632,066 shares or 2.72% stake. With a 2.16% stake in VTGN, the iShares Russell 2000 ETF is the largest stakeholder. A total of 4,464,853 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.17% of VTGN stock, is the second-largest Mutual Fund holder. It holds 2,422,862 shares valued at 0.25 million. Government Pension Fund – Global holds 0.93% of the stake in VTGN, owning 1,928,962 shares worth 0.2 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VTGN since 2 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VTGN analysts setting a high price target of $0.25 and a low target of $0.25, the average target price over the next 12 months is $0.25. Based on these targets, VTGN could surge 38.89% to reach the target high and rise by 38.89% to reach the target low. Reaching the average price target will result in a growth of 38.89% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. VTGN will report FY 2023 earnings on 06/27/2023. Analysts have provided yearly estimates in a range of -$0.28 being high and -$0.35 being low. For VTGN, this leads to a yearly average estimate of -$0.32. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. VistaGen Therapeutics Inc. surprised analysts by -$0.01 when it reported -$0.08 EPS against a consensus estimate of -$0.07. The surprise factor in the prior quarter was -$0.02. Based on analyst estimates, the high estimate for the next quarter is -$0.06 and the low estimate is -$0.08. The average estimate for the next quarter is thus -$0.07.

Summary of Insider Activity:

Insiders traded VTGN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 8 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 1,215,000 while 60,000 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *